Track the Canadian Junior Mining Market at the speed of AI

Build a portfolio of Canadian junior mining companies on 6ix and get real-time updates the minute they announce something. Discover investor events, company profiles, and news in one place.

Please enable JavaScript to use all features of 6ix.com.

Latest Press Releases

Time	Headline
1h ago	The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
1h ago	Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO Sichuan Kelun-biotech Biopharmaceutical Co., Ltd. Class H
1h ago	Max Power Mining Closes $25 Million Strategic Investment From Eric Sprott To Accelerate Commercial Evaluation at Lawson Max Power Mining Corp
2h ago	Mach Travel Solutions Delivers Sustained FY26 Performance Despite Challenging Macro- Economic Environment; While Accelerating Transformation into an Integrated Travel Solutions Platform Mach Conferences And Events Ltd.
2h ago	Vanta Announces Strategic Private Placement Financing to Advance U.S. Peptide Market Entry and Integrated Longevity and Consumer Health Sciences Platform Vanta Holdings Inc.

About

1.64USD-0.03 -1.80%

Closed • Updated at 05:11 GMT+00:00

Market Cap$26.09M

Volume215.1K

Beta0.79

RSI58.11

Gross Margin100.00%

Health TechnologyPharmaceuticals: Major

Allarity Therapeutics, Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm

Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

Allarity Therapeutics Presents Two AACR 2026 Posters Highlighting Stenoparib’s Potential in Colorectal Cancer as well as New Predictive Data Linking DRP® and Overall Survival in Ovarian Cancer

Recent Videos

ALLR: CEO Speaking - My Take on the 8-K

ALLR: CEO Speaking - My Take on the 8-K

May 11, 2026

ALLR STOCK : POTENTIAL RECOVERY | ALLARITY THERAPEUTICS STOCK

ALLR STOCK : POTENTIAL RECOVERY | ALLARITY THERAPEUTICS STOCK

Apr 11, 2026

🟢344.- (ALLR) 🇺🇸 $1.25 Allarity Therapeutics incr ⭐️⭐️⭐️ Morningstar

🟢344.- (ALLR) 🇺🇸 $1.25 Allarity Therapeutics incr ⭐️⭐️⭐️ Morningstar

Mar 07, 2026

🟢344.- (ALLR) 🇺🇸 $1.25 Allarity Therapeutics incr ⭐️⭐️⭐️ Morningstar

🟢344.- (ALLR) 🇺🇸 $1.25 Allarity Therapeutics incr ⭐️⭐️⭐️ Morningstar

Mar 07, 2026

Community Chat

Ask AI

Try asking